Metagenomi to present at upcoming scientific meetings

-   oral presentation at world federation of hemophilia (wfh) world congress,  april 23, 2024 -   two posters at american society of gene & cell therapy (asgct) 2024 annual meeting, may 8 & 9, 2024 emeryville, calif., april 08, 2024 (globe newswire) -- metagenomi, inc. (nasdaq: mgx), a precision genetic medicines company committed to developing curative therapeutics for patients using its proprietary, comprehensive metagenomics-derived gene editing toolbox, today announced that the company will present at two upcoming scientific meetings: a late breaking oral presentation at the world federation of hemophilia (wfh) world congress, taking place april 21 – 24, 2024 in madrid, spain and two poster presentations at the american society of gene & cell therapy (asgct) 2024 annual meeting, taking place may 7 – 11, 2024, in baltimore, md and virtually.
MGX Ratings Summary
MGX Quant Ranking